for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

United Therapeutics Corporation

UTHR.O

Latest Trade

203.16USD

Change

1.49(+0.74%)

Volume

31,169

Today's Range

200.94

 - 

204.59

52 Week Range

94.26

 - 

204.78

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
201.67
Open
203.34
Volume
31,169
3M AVG Volume
7.94
Today's High
204.59
Today's Low
200.94
52 Week High
204.78
52 Week Low
94.26
Shares Out (MIL)
44.54
Market Cap (MIL)
9,032.70
Forward P/E
15.88
Dividend (Yield %)
--

Next Event

Q1 2021 United Therapeutics Corp Earnings Release

Latest Developments

More

United Therapeutics Announces FDA Approval And Launch Of Tyvaso® For The Treatment Of Pulmonary Hypertension Associated With Interstitial Lung Disease

United Therapeutics Says Decided To Discontinue Development Of Trevyent Due To Written Comments Provided By FDA On Feb 25

United Therapeutics Corp Reports Fourth Quarter And Full Year 2020 Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.

Industry

Biotechnology & Drugs

Contact Info

1040 SPRING ST

SILVER SPRING, MD

20910

United States

+1.301.6089292

http://www.unither.com

Executive Leadership

Martine A. Rothblatt

Chairman of the Board, Chief Executive Officer

Michael Benkowitz

President, Chief Operating Officer

Christopher Patusky

Lead Independent Vice Chairman of the Board

James C. Edgemond

Chief Financial Officer, Treasurer

Paul A. Mahon

Executive Vice President, General Counsel, Corporate Secretary

Key Stats

2.09 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

1.6K

2019

1.4K

2020

1.5K

2021(E)

1.6K
EPS (USD)

2018

13.390

2019

-2.390

2020

11.540

2021(E)

12.768
Price To Earnings (TTM)
17.54
Price To Sales (TTM)
6.09
Price To Book (MRQ)
2.66
Price To Cash Flow (TTM)
16.00
Total Debt To Equity (MRQ)
23.56
LT Debt To Equity (MRQ)
23.56
Return on Investment (TTM)
13.30
Return on Equity (TTM)
12.07

Latest News

Latest News

Israel deal should remove any hurdle to F-35 sale, UAE official says

The United Arab Emirates' accord to normalise ties with Israel should remove "any hurdle" for the United States to sell the F-35 stealth fighter jet to the Gulf Arab state, a senior Emirati official said on Thursday.

BRIEF-Liquidia Responds To United Therapeutics Corporation Lawsuit

* LIQUIDIA RESPONDS TO UNITED THERAPEUTICS CORPORATION LAWSUIT

BRIEF-United Therapeutics Files Lawsuit Against Liquidia For Infringement Of Tyvaso Patents

* UNITED THERAPEUTICS CORP - FILES LAWSUIT AGAINST LIQUIDIA FOR INFRINGEMENT OF TYVASO PATENTS

BRIEF-Medicenna Therapeutics Expect To Complete IND Enabling Studies For MDNA109 Superkine Platform By Q1

* MEDICENNA THERAPEUTICS - END OF PHASE 2 MEETING PACKAGE FOR MDNA55 TO BE SUBMITTED IN Q2 2020

BRIEF-United Therapeutics Announces Additional Results From Freedom-Ev Study Showing Hemodynamic And Risk Status Reduction Benefits Of Orenitram Treatment In Patients With Pulmonary Arterial Hypertension

* UNITED THERAPEUTICS ANNOUNCES ADDITIONAL RESULTS FROM FREEDOM-EV STUDY SHOWING THE HEMODYNAMIC AND RISK STATUS REDUCTION BENEFITS OF ORENITRAM TREATMENT IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

BRIEF-United Therapeutics Says Chairman And CEO Martine Rothblatt's 2019 Total Compensation Was $45.6 Mln Versus $16 Mln In 2018

* UNITED THERAPEUTICS CORP - CHAIRMAN AND CEO MARTINE ROTHBLATT'S 2019 TOTAL COMPENSATION WAS $45.6 MILLION VERSUS $16 MILLION IN 2018 - SEC FILING

BRIEF-Celularity Expands Strategic Collaboration With United Therapeutics

* CELULARITY EXPANDS STRATEGIC COLLABORATION WITH UNITED THERAPEUTICS CORPORATION TO COVID-19 INFECTION AND ACUTE RESPIRATORY DISTRESS SYNDROME

BRIEF-United Therapeutics Corporation Reports Q4 Adjusted Earnings Per Share $1.96

* ORATION REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

United Therapeutics notches win in fight over blocked generic rival

United Therapeutics Corp can continue to restrict how pharmacies dispense delivery devices for its cardiovascular drug Remodulin, a New Jersey federal judge ruled on Wednesday, dealing a setback to Novartis AG' Sandoz generic drug unit.

Arena Pharma soars on deal with United Therapeutics for hypertension drug

Shares of Arena Pharmaceuticals Inc jumped nearly 30 percent after the drug developer sold rights to develop and sell its hypertension treatment to United Therapeutics Corp, fetching it $800 million in an upfront payment.

BRIEF-United Therapeutics Reports Q1 Adj. Earnings Per Share Of $3.76

* Q1 EARNINGS PER SHARE VIEW $3.52 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-United Therapeutics To Acquire SteadyMed Ltd

* UNITED THERAPEUTICS-TRANSACTION, INCLUDING $75 MILLION IN CONTINGENT CONSIDERATION, IS VALUED AT $216 MILLION

BRIEF-United Therapeutics Says CEO Martine Rothblatt's FY 2017 Total Compensation Was $37.1 Mln

* UNITED THERAPEUTICS SAYS CEO MARTINE ROTHBLATT'S FY 2017 TOTAL COMPENSATION WAS $37.1 MILLION WHICH INCLUDED $33.1 MILLION IN OPTION/STAP AWARDS - SEC FILING

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up